For all the background parameters sick ...

For all the background parameters of the patients differed significantly from the group of healthy subjects [4,6]. On the seventh day of therapy, 65% of patients noted significant improvement in subjective well-being, significantly improved performance according to questionnaire testing. By day 28, treatment of all study patients noted significant improvement in subjective well-being (VAS score of 6.55 before treatment, after - 3.84 points), a decrease of expression of asthenic manifestations (overall score of severity of fatigue was significantly decreased during treatment from 18.1 to 11 , 5 points), significantly improved the quality of nighttime sleep (from 17.9 to 20.75 points in therapy), a decrease of expression of anxiety and depressive manifestations (from 52.8 points to 42.9 points and 16.25 points to 10 , 55 points, respectively), reducing the severity of vegetative dystonia (44.8 points before treatment and after 33.22) (Table 1). In the analysis of cognitive function before treatment revealed that the surveyed our patients compared with healthy subjects there was significantly less than memorizing a digit (short-term visual memory of figures) and images (short-term visual memory for images), significantly impeded mediated memorizing (ability not only to keep in mind again assimilate information, but also the opportunity to operate it), significantly worse than the concentration of attention (the average time spent in the five black and white tables Schulte and the number of errors in the test Bourdon) and efficiency (number of lines scanned in the test Bourdon ). By 28 th day of therapy, all parameters significantly improved compared with the background, without reaching the values ??of healthy subjects, but did not differ from them significantly (Table 2). The study of evoked potentials P300, as measured as a correlate of memory and the level of focused attention, revealed the following: the amplitude-temporal parameters of the P300 did not have significant differences in latent periods compared with healthy subjects. Before treatment showed a significant decrease in the amplitude of component P300 (4,31 ± 0,51 mV) compared with healthy subjects in 2,5 times (12,78 ± 0,58 mV), indicating that a violation of focused attention and difficulty concentrating. After treatment, observed a significant increase in the amplitude of the P300 component in patients (7,06 ± 0,54 mV) compared with its original background, but this increase did not reach the values ??of healthy subjects. Effectiveness of the drug was evaluated based on the total index score of fatigue on day 28 of therapy. All examined our patients were divided into three groups: Group 1 - high efficiency - Score 18 points. At the 28-day therapy in patients with unsatisfactory performance (ie belonging to the third group) was not, in the second group included 10 patients (25%) in the first 30 patients (75%). Patients of the first group of asthenic complaints range regressed completely. Patients of the second group had a significantly greater duration of disease (17,5 ± 3,1 months) compared with patients of the first group (7,4 ± 2,6 months) and significantly higher percentage of combinations of factors leading to the appearance of asthenia (100% in the second group and 33.3% in the first).